Brief: EMA's CHMP Recommended Five Extensions Of Indication For Medicines Bimervax, Dupixent, Keytruda
19/09/2025 11:17
Sept 19 (Reuters) - EMA's CHMP: EMA'S CHMP: RECOMMENDED FIVE EXTENSIONS OF INDICATION FOR MEDICINES BIMERVAX, DUPIXENT, KEYTRUDA EMA'S CHMP: RECOMMENDED GRANTING MARKETING AUTHORISATION FOR IMAAVY (NIPOCALIMAB) EMA'S CHMP: POSITIVE OPINION WAS ADOPTED FOR KYINSU (INSULIN ICODEC / SEMAGLUTIDE) EMA'S CHMP: FOLLOWING RE-EXAMINATION, RECOMMENDED GRANTING MARKETING AUTHORISATION FOR WINLEVI (CLASCOTERONE) EMA'S CHMP: WITHDRAWAL OF INITIAL MARKETING AUTHORISATION APPLICATION FOR IOVANCE BIOTHERAPEUTICS B.V.'S AMTAGVI MEDICINE ((Reuters.Briefs@thomsonreuters.com))
Recent news on Iovance Biotherapeutics
See all newsBrief: Iovance Biotherapeutics Reports Inducement Grants
US RESEARCH ROUNDUP-BlackRock, Evercore, Goldman Sachs
Brief: Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., As Chief Medical Officer
Iovance hits two-year high after raising annual revenue forecast
U.S. RESEARCH ROUNDUP- Berkshire Hathaway, Exxon Mobil, Honeywell Technologies